All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 65 points (0.4%) at 17,698 as of Wednesday, March 30, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,906 issues advancing vs. 1,052 declining with 157 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include

Valeant Pharmaceuticals International

(

VRX

), down 5.1%,

Medivation

(

MDVN

), down 4.1%,

Regeneron Pharmaceuticals

(

REGN

), down 1.8%,

Vertex Pharmaceuticals

(

VRTX

), down 1.6% and

Teva Pharmaceutical Industries

(

TEVA

), down 1.3%. A company within the industry that increased today was

ACADIA Pharmaceuticals

(

ACAD

), up 7.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Illumina

(

ILMN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Illumina is down $1.19 (-0.8%) to $155.94 on average volume. Thus far, 614,625 shares of Illumina exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $155.56-$162.92 after having opened the day at $158.99 as compared to the previous trading day's close of $157.13.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. Illumina has a market cap of $22.4 billion and is part of the health care sector. Shares are down 18.1% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Illumina

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Illumina Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mylan

(

MYL

) is down $0.82 (-1.8%) to $46.18 on light volume. Thus far, 1.1 million shares of Mylan exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $46.03-$47.20 after having opened the day at $46.97 as compared to the previous trading day's close of $47.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $22.2 billion and is part of the health care sector. Shares are down 13.1% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Mylan a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Amgen

(

AMGN

) is down $0.90 (-0.6%) to $148.59 on light volume. Thus far, 1.0 million shares of Amgen exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $148.30-$150.88 after having opened the day at $149.90 as compared to the previous trading day's close of $149.49.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen has a market cap of $111.6 billion and is part of the health care sector. Shares are down 7.9% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).